MRI-based prediction of conversion from clinically isolated syndrome to clinically definite multiple sclerosis using SVM and lesion geometry.
Classification
Clinically isolated syndrome
Lesion geometry
MRI
Multiple sclerosis
Support vector machine
Journal
Brain imaging and behavior
ISSN: 1931-7565
Titre abrégé: Brain Imaging Behav
Pays: United States
ID NLM: 101300405
Informations de publication
Date de publication:
Oct 2019
Oct 2019
Historique:
pubmed:
30
8
2018
medline:
1
2
2020
entrez:
30
8
2018
Statut:
ppublish
Résumé
Neuroanatomical pattern classification using support vector machines (SVMs) has shown promising results in classifying Multiple Sclerosis (MS) patients based on individual structural magnetic resonance images (MRI). To determine whether pattern classification using SVMs facilitates predicting conversion to clinically definite multiple sclerosis (CDMS) from clinically isolated syndrome (CIS). We used baseline MRI data from 364 patients with CIS, randomised to interferon beta-1b or placebo. Non-linear SVMs and 10-fold cross-validation were applied to predict converters/non-converters (175/189) at two years follow-up based on clinical and demographic data, lesion-specific quantitative geometric features and grey-matter-to-whole-brain volume ratios. We applied linear SVM analysis and leave-one-out cross-validation to subgroups of converters (n = 25) and non-converters (n = 44) based on cortical grey matter segmentations. Highest prediction accuracies of 70.4% (p = 8e-5) were reached with a combination of lesion-specific geometric (image-based) and demographic/clinical features. Cortical grey matter was informative for the placebo group (acc.: 64.6%, p = 0.002) but not for the interferon group. Classification based on demographic/clinical covariates only resulted in an accuracy of 56% (p = 0.05). Overall, lesion geometry was more informative in the interferon group, EDSS and sex were more important for the placebo cohort. Alongside standard demographic and clinical measures, both lesion geometry and grey matter based information can aid prediction of conversion to CDMS.
Identifiants
pubmed: 30155789
doi: 10.1007/s11682-018-9942-9
pii: 10.1007/s11682-018-9942-9
pmc: PMC6733701
mid: EMS82960
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1361-1374Subventions
Organisme : Wellcome Trust
ID : 100309
Pays : United Kingdom
Références
Phys Rev E Stat Nonlin Soft Matter Phys. 2001 Mar;63(3 Pt 1):031112
pubmed: 11308635
Ann Neurol. 2001 Jul;50(1):121-7
pubmed: 11456302
J Microsc. 2001 Sep;203(Pt 3):303-13
pubmed: 11555148
Mult Scler. 2001 Dec;7(6):359-63
pubmed: 11795456
N Engl J Med. 2002 Jan 17;346(3):158-64
pubmed: 11796849
Nat Neurosci. 2003 May;6(5):448-50
pubmed: 12704393
J Magn Reson Imaging. 2003 Sep;18(3):291-301
pubmed: 12938123
Brain. 2004 May;127(Pt 5):1101-7
pubmed: 14998914
Mult Scler. 2004 Aug;10(4):402-6
pubmed: 15327037
Mult Scler. 2004 Oct;10(5):562-8
pubmed: 15471374
J Neuroimaging. 2005 Jan;15(1):27-36
pubmed: 15574571
Ann Neurol. 2005 Feb;57(2):210-5
pubmed: 15668965
Brain. 2005 Jun;128(Pt 6):1454-60
pubmed: 15817511
Ann Neurol. 2005 Dec;58(6):840-6
pubmed: 16283615
J Neuroimaging. 2005;15(4 Suppl):30S-45S
pubmed: 16385017
Brain. 2006 Mar;129(Pt 3):606-16
pubmed: 16415308
Neurology. 2006 Feb 28;66(4):551-6
pubmed: 16505310
Neurology. 2006 Oct 10;67(7):1242-9
pubmed: 16914693
Neurology. 2006 Sep 26;67(6):968-72
pubmed: 17000962
Lancet. 2007 Aug 4;370(9585):389-97
pubmed: 17679016
Arch Neurol. 2007 Sep;64(9):1292-8
pubmed: 17846268
Neurology. 2008 Mar 25;70(13 Pt 2):1079-83
pubmed: 17881717
J Neurol. 2008 Apr;255(4):480-7
pubmed: 18004635
Brain. 2008 Mar;131(Pt 3):808-17
pubmed: 18234696
Neuroimage. 2008 Aug 1;42(1):315-22
pubmed: 18501636
Comput Stat Data Anal. 2008 Jan 15;53(3):820-833
pubmed: 19177180
J Neurol Sci. 2009 Jul 15;282(1-2):47-54
pubmed: 19201003
Lancet Neurol. 2009 Nov;8(11):987-97
pubmed: 19748319
AJNR Am J Neuroradiol. 2010 Jun;31(6):983-9
pubmed: 20019103
Brain. 2010 Jul;133(Pt 7):1914-29
pubmed: 20534650
Nat Rev Neurol. 2010 Aug;6(8):438-44
pubmed: 20625376
Schizophr Res. 2010 Nov;123(2-3):160-74
pubmed: 20826078
Radiology. 2010 Nov;257(2):448-54
pubmed: 20858849
J Neurol Neurosurg Psychiatry. 2011 Sep;82(9):1017-21
pubmed: 21297149
Neurology. 2011 Jul 19;77(3):257-63
pubmed: 21613600
PLoS One. 2011;6(6):e21138
pubmed: 21695053
Stat Med. 2012 Feb 28;31(5):449-69
pubmed: 21964585
Neurosci Biobehav Rev. 2012 Apr;36(4):1140-52
pubmed: 22305994
Lancet Neurol. 2012 Apr;11(4):349-60
pubmed: 22441196
Mult Scler. 2012 Nov;18(11):1577-84
pubmed: 22495945
AJNR Am J Neuroradiol. 2012 Sep;33(8):1573-8
pubmed: 22499842
Brain. 2013 Apr;136(Pt 4):1012-24
pubmed: 23412934
Mult Scler. 2013 Dec;19(14):1878-86
pubmed: 23652215
Continuum (Minneap Minn). 2013 Aug;19(4 Multiple Sclerosis):901-21
pubmed: 23917093
Neuroimage Clin. 2013 May 19;2:735-45
pubmed: 24179825
Ann Appl Stat. 2014;8(2):1095-1118
pubmed: 25431633
Neuroimage Clin. 2014 Dec 04;7:281-7
pubmed: 25610791
J Neuroimaging. 2017 Nov;27(6):613-619
pubmed: 28488804
Neuroepidemiology. 1994;13(1-2):14-8
pubmed: 8190201
Hum Immunol. 1993 Jul;37(3):185-91
pubmed: 8244781
Brain. 1993 Feb;116 ( Pt 1):135-46
pubmed: 8453454
Brain. 1998 Mar;121 ( Pt 3):495-503
pubmed: 9549525